The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
暂无分享,去创建一个
E. Martı́n-Mola | C. Plasencia | A. Balsa | L. Lojo | D. Pascual‐Salcedo | S. García-Carazo | L. Nuño | A. Villalba | D. Peiteado | F. Arribas | J. Díez | M. López-Casla